Strength training and testosterone treatment have opposing effects on migration inhibitor factor levels in ageing men

D Glintborg, L L Christensen, T Kvorning, R Larsen, K Brixen, D M Hougaard, B Richelsen, J M Bruun, M Andersen, D Glintborg, L L Christensen, T Kvorning, R Larsen, K Brixen, D M Hougaard, B Richelsen, J M Bruun, M Andersen

Abstract

Background: The beneficial effects of testosterone treatment (TT) are debated.

Methods: Double-blinded, placebo-controlled study of six months TT (gel) in 54 men aged 60-78 with bioavailable testosterone (BioT) <7.3 nmol/L and waist >94 cm randomized to TT (50-100 mg/day, n = 20), placebo (n = 18), or strength training (ST) (n = 16) for 24 weeks. Moreover, the ST group was randomized to TT (n = 7) or placebo (n = 9) after 12 weeks.

Outcomes: Chemokines (MIF, MCP-1, and MIP-1 α ) and lean body mass (LBM), total, central, extremity, visceral, and subcutaneous (SAT) fat mass established by DXA and MRI. Results. From 0 to 24 weeks, MIF and SAT decreased during ST + placebo versus placebo, whereas BioT and LBM were unchanged. TT decreased fat mass (total, central, extremity, and SAT) and increased BioT and LBM versus placebo. MIF levels increased during TT versus ST + placebo. ST + TT decreased fat mass (total, central, and extremity) and increased BioT and LBM versus placebo. From 12 to 24 weeks, MCP-1 levels increased during TT versus placebo and MCP-1 levels decreased during ST + placebo versus placebo.

Conclusion: ST + placebo was associated with decreased MIF levels suggesting decreased inflammatory activity. TT may be associated with increased inflammatory activity.

Trial registration: ClinicalTrials.gov NCT00700024.

Figures

Figure 1
Figure 1
Study design.

References

    1. Frederiksen L, Højlund K, Hougaard DM, Brixen K, Andersen M. Testosterone therapy increased muscle mass and lipid oxidation in aging men. Age. 2012;34(1):145–156.
    1. Dandona P, Dhindsa S. Update: hypogonadotropic hypogonadism in type 2 diabetes and obesity. Journal of Clinical Endocrinology and Metabolism. 2011;96(9):2643–2651.
    1. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. The New England Journal of Medicine. 2010;363(2):109–122.
    1. Frederiksen L, Højlund K, Hougaard DM, et al. Testosterone therapy decreases subcutaneous fat and adiponectin in aging men. European Journal of Endocrinology. 2012;166(3):469–476.
    1. Frederiksen L, Glintborg D, Hojlund K, et al. Osteoprotegerin levels decrease during testosterone therapy in aging men and are associated with changed distribution of regional fat. Hormone and Metabolic Research. 2013;45(4):308–313.
    1. Fernández-Balsells MM, Murad MH, Lane M, et al. Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. Journal of Clinical Endocrinology and Metabolism. 2010;95(6):2560–2575.
    1. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365(9468):1415–1428.
    1. Fasshauer M, Paschke R. Regulation of adipocytokines and insulin resistance. Diabetologia. 2003;46(12):1594–1603.
    1. Fain JN, Tichansky DS, Madan AK. Most of the interleukin 1 receptor antagonist, cathepsin S, macrophage migration inhibitory factor, nerve growth factor, and interleukin 18 release by explants of human adipose tissue is by the non-fat cells, not by the adipocytes. Metabolism. 2006;55(8):1113–1121.
    1. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW., Jr. Obesity is associated with macrophage accumulation in adipose tissue. Journal of Clinical Investigation. 2003;112(12):1796–1808.
    1. Bruun JM, Lihn AS, Pedersen SB, Richelsen B. Monocyte chemoattractant protein-1 release is higher in visceral than subcutaneous human adipose tissue (AT): implication of macrophages resident in the AT. Journal of Clinical Endocrinology and Metabolism. 2005;90(4):2282–2289.
    1. Dandona P, Aljada A, Ghanim H, et al. Increased plasma concentration of macrophage Migration Inhibitory Factor (MIF) and MIF mRNA in mononuclear cells in the obese and the suppressive action of metformin. Journal of Clinical Endocrinology and Metabolism. 2004;89(10):5043–5047.
    1. Church TS, Willis MS, Priest EL, et al. Obesity, macrophage migration inhibitory factor, and weight loss. International Journal of Obesity. 2005;29(6):675–681.
    1. Christiansen T, Richelsen B, Bruun JM. Monocyte chemoattractant protein-1 is produced in isolated adipocytes, associated with adiposity and reduced after weight loss in morbid obese subjects. International Journal of Obesity. 2005;29(1):146–150.
    1. Westerbacka J, Kolak M, Kiviluoto T, et al. Genes involved in fatty acid partitioning and binding, lipolysis, monocyte/macrophage recruitment, and inflammation are overexpressed in the human fatty liver of insulin-resistant subjects. Diabetes. 2007;56(11):2759–2765.
    1. Sell H, Eckel J. Monocyte chemotactic protein-1 and its role in insulin resistance. Current Opinion in Lipidology. 2007;18(3):258–262.
    1. Herder C, Klopp N, Baumert J, et al. Effect of macrophage migration inhibitory factor (MIF) gene variants and MIF serum concentrations on the risk of type 2 diabetes: results from the MONICA/KORA Augsburg Case-Cohort Study, 1984–2002. Diabetologia. 2008;51(2):276–284.
    1. Nielsen TL, Hagen C, Wraae K, et al. Visceral and subcutaneous adipose tissue assessed by magnetic resonance imaging in relation to circulating androgens, sex hormone-binding globulin, and luteinizing hormone in young men. Journal of Clinical Endocrinology and Metabolism. 2007;92(7):2696–2705.
    1. Cooper C, Dere W, Evans W, et al. Frailty and sarcopenia: definitions and outcome parameters. Osteoporosis International. 2012;7:1839–1848.
    1. Isidori AM, Giannetta E, Greco EA, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clinical Endocrinology. 2005;63(3):280–293.
    1. Kvorning T, Christensen LL, Madsen K, et al. Mechanical muscle function and lean body mass during supervised strength training and testosterone therapy in aging men with low normal testosterone levels—a placebo-controlled, randomized, double-blind study. Journal of the American Geriatrics Society. 2013;61(6):957–962.
    1. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. Journal of Clinical Endocrinology and Metabolism. 1999;84(10):3666–3672.
    1. Mosbech TH, Pilgaard K, Vaag A, Larsen R. Automatic segmentation of abdominal adipose tissue in MRI. Lecture Notes in Computer Science. 2011;6688:501–511.
    1. Corona G, Rastrelli G, Vignozzi L, Mannucci E, Maggi M. Testosterone, cardiovascular disease and the metabolic syndrome. Best Practice and Research. 2011;25(2):337–353.
    1. Aloisi AM, Pari G, Ceccarelli I, et al. Gender-related effects of chronic non-malignant pain and opioid therapy on plasma levels of macrophage migration inhibitory factor (MIF) Pain. 2005;115(1-2):142–151.
    1. Glintborg D, Andersen M, Richelsen B, Bruun JM. Plasma monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1α are increased in patients with polycystic ovary syndrome (PCOS) and associated with adiposity, but unaffected by pioglitazone treatment. Clinical Endocrinology. 2009;71(5):652–658.
    1. Christiansen JJ, Bruun JM, Christiansen JS, Jørgensen JO, Gravholt CH. Long-term DHEA substitution in female adrenocortical failure, body composition, muscle function, and bone metabolism: a randomized trial. European Journal of Endocrinology. 2011;165(2):293–300.
    1. Meinhardt A, Bacher M, Wennemuth G, Eickhoff R, Hedger M. Macrophage migration inhibitory factor (MIF) as a paracrine mediator in the interaction of testicular somatic cells. Andrologia. 2000;32(1):46–48.
    1. Charo IF, Ransohoff RM. Mechanisms of disease: the many roles of chemokines and chemokine receptors in inflammation. The New England Journal of Medicine. 2006;354(6):610–621.
    1. Kleemann R, Bucala R. Macrophage migration inhibitory factor: critical role in obesity, insulin resistance, and associated comorbidities. Mediators of Inflammation. 2010;2010:7 pages.610479
    1. Bruun JM, Helge JW, Richelsen B, Stallknecht B. Diet and exercise reduce low-grade inflammation and macrophage infiltration in adipose tissue but not in skeletal muscle in severely obese subjects. American Journal of Physiology. Endocrinology and Metabolism. 2006;290(5):E961–E967.
    1. Harman-Boehm I, Blüher M, Redel H, et al. Macrophage infiltration into omental versus subcutaneous fat across different populations: effect of regional adiposity and the comorbidities of obesity. Journal of Clinical Endocrinology and Metabolism. 2007;92(6):2240–2247.
    1. Klein S, Fontana L, Young L, et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. The New England Journal of Medicine. 2004;350(25):2549–2557.
    1. Karastergiou K, Smith SR, Greenberg AS, Fried SK. Sex differences in human adipose tissues—the biology of pear shape. Biology of Sex Differences. 2012;1(article 13)
    1. Frederiksen L, Nielsen TL, Wraae K, et al. Subcutaneous rather than visceral adipose tissue is associated with adiponectin levels and insulin resistance in young men. Journal of Clinical Endocrinology and Metabolism. 2009;94(10):4010–4015.
    1. Lucotti P, Monti LD, Setola E, et al. Aerobic and resistance training effects compared to aerobic training alone in obese type 2 diabetic patients on diet treatment. Diabetes Research and Clinical Practice. 2011;94(3):395–403.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe